Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Depreciation & Amortization (CF) (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Depreciation & Amortization (CF) for 2 consecutive years, with $165789.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) changed 0.2% to $165789.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $662637.0, a 99.69% increase, with the full-year FY2025 number at $662890.0, changed 0.02% from a year prior.
  • Depreciation & Amortization (CF) was $165789.0 for Q4 2025 at Neuphoria Therapeutics, roughly flat from $165792.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $166121.0 in Q4 2024 to a low of $165431.0 in Q1 2025.